

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Chronic obstructive pulmonary disease exacerbation purulence status and its association with pulmonary embolism: protocol for a systematic review with meta-analysis

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2024-085328 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 12-Feb-2024 |
| Complete List of Authors: | Mai, Vicky; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute Girardi, Laura; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute; University of Insubria, Department of Medicine and Surgery de Wit, Kerstin; Queens University, Department of Emergency Medicine and Medicine Castellucci, Lana; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute Aaron, Shawn; University of Ottawa, Department of Medicine Couturaud, Francis; Centre Hospitalier Universitaire de Brest, Département de Médecine Interne et Pneumologie Fergusson, Dean; Ottawa Hospital Research Institute, Clinical Epidemiology Le Gal, Grégoire; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute |
| Keywords: | Pulmonary Disease, Chronic Obstructive, Thromboembolism < CARDIOLOGY, Respiratory infections < THORACIC MEDICINE, Epidemiology < THORACIC MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Chronic obstructive pulmonary disease exacerbation purulence status and its association**
4
5 **with pulmonary embolism: protocol for a systematic review with meta-analysis**
6
7

8
9
10 Vicky Mai¹, Laura Girardi^{1,2}, Kerstin de Wit³, Lana A. Castellucci¹, Shawn Aaron⁴, Francis
11
12 Couturaud⁵, Dean Fergusson⁶, Grégoire Le Gal¹
13
14

15
16
17 ¹ Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa,
18
19 Canada.
20

21 ² Department of Medicine and Surgery, University of Insubria, Varese, Italy.
22

23 ³ Department of Emergency Medicine and Medicine, Queens University, Kingston.
24

25
26 ⁴ Department of Medicine, Faculty of Medicine, Division of Respiriology, University of Ottawa,
27
28 Ottawa, Ontario, Canada.
29

30
31 ⁵ INSERM U1304-GETBO, CIC INSERM 1412, Univ_Brest, Département de Médecine Interne
32
33 et Pneumologie, CHU_Brest, Brest, FCRIN INNOVTE, France.
34

35
36 ⁶ Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
37
38
39
40
41
42
43
44

45 **Corresponding author:**

46 Grégoire Le Gal
47 Ottawa Hospital Research Institute – University of Ottawa
48 501 Smyth Road, Ottawa, ON, Canada, K1H 8L6
49 E-mail: glegal@toh.ca
50

51
52 Abstract word count: 282

53 Manuscript word count: 1743
54
55
56
57
58
59
60

ABSTRACT

Introduction: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) increases the risk of pulmonary embolism (PE). AECOPD and PE have similar symptoms which results in a high proportion of patients with AECOPD undergoing imaging to rule out PE. Finding predictors and explanatory factors of PE in AECOPD, such as purulence status, could help reduce the need for imaging. This systematic review with meta-analysis aims to evaluate if there is an association between purulence status in AECOPD and PE diagnosis.

Methods and analysis: MEDLINE, EMBASE and CENTRAL will be searched from inception to March 2023. Randomized trials, cohort studies and cross-sectional studies on the prevalence of PE in patients with AECOPD will be included if the prevalence of PE based on the AECOPD purulence status is available. The primary outcome will be PE at the initial assessment and secondary outcomes will be all venous thromboembolism (deep venous thrombosis (DVT) and PE) and DVT, respectively, diagnosed at initial assessment. Relative risks (RR) with their 95% confidence interval (CI) will be calculated by using a Mantel-Haenszel random-effect model to compare the association between the risk of PE and the AECOPD purulence status (purulent vs non-purulent/unknown). Subgroup analyses will be performed based on the type of study, systematic search of PE vs no systematic search of PE and localization of PE. Risk of bias will be evaluated by the ROBINS-E tool, publication bias will be evaluated with the funnel plot. The manuscript will be drafted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.

1
2
3 **Ethics and dissemination:** This study does not require ethics approval. This work will be
4 submitted for presentation in an international conference and for publication in a peer-reviewed
5 journal.
6
7
8
9

10 **PROSPERO registration number:** CRD42023459429
11
12
13

14 **Strengths and limitations of the study**

- 15 • This will be the first systematic review with meta-analysis evaluating the association
16 between the risk of pulmonary embolism (PE) and the acute exacerbation of chronic
17 obstructive pulmonary disease (AECOPD) purulence status.
18
- 19 • The AECOPD purulence status may not be homogenous across studies, which may make
20 it more challenging to pool some data.
21
- 22 • This study has the potential to improve PE diagnostic management in patients with
23 AECOPD.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) increases the risk of pulmonary embolism (PE)¹ due to increased systemic inflammation as well as in the airways². Moreover, PE is associated with a 5-fold increased risk of mortality in patients with chronic obstructive pulmonary disease (COPD)³. Diagnosing PE in the context of AECOPD is challenging for several reasons. First, due to confounding symptoms of AECOPD and PE, it is unknown when PE should be suspected in patients with COPD. Second, even when PE is not suspected, or when another diagnosis is more likely, the prevalence of PE [i.e., 4.5% (PEP⁴ and SLICE⁵)] is not low enough to safely exclude PE on clinical grounds only. Clinical decision rules and D-dimers, when applied to patients with AECOPD and whether PE is suspected or not, have lower clinical utility in AECOPD, since > 65% of the patients would need imaging to rule out PE if standard diagnostic strategy were used⁴. In addition, negative effects are seen with computed tomography pulmonary angiogram (CTPA) such as cost, radiation exposure, contrast-induced nephropathy, and incidental findings. Furthermore, as the severity of the COPD progresses, AECOPD occurs more frequently⁶ and it is expected that the need to rule out PE will become more frequent. Finding predictors and explanatory factors of PE in AECOPD, such as the purulence status, could help reduce the need for imaging. Clinically, it would make sense that if the AECOPD is explained by an infectious process, then the PE would be less likely and conversely, if the AECOPD is unexplained, it would make sense that PE would be more likely to be the explanation for the AECOPD.

Thus, the aim of this systematic review with meta-analysis is to evaluate whether purulence status in AECOPD is associated with PE. We hypothesize that the risk of PE will be lower in purulent AECOPD compared to non-purulent or unknown purulent status AECOPD, since the etiology of

1
2
3 the exacerbation is unknown in up to 30% of the AECOPD⁷ and PE could thus be an explanation
4
5 in those cases.
6
7
8
9

10 **STUDY OBJECTIVES**

11 **Primary objective**

12
13
14 The primary objective is to evaluate the risk of PE in patients with purulent AECOPD compared
15
16 to non-purulent or unknown purulent status AECOPD.
17
18

19 **Secondary objective**

20
21 The secondary objective is to evaluate the risk of venous thromboembolism (VTE) [including deep
22
23 venous thrombosis (DVT) of the lower extremity and PE] and the risk of DVT, respectively, in
24
25 patients with purulent AECOPD compared to non-purulent or unknown purulent status AECOPD.
26
27
28
29

30 **METHODS AND ANALYSIS**

31 **Eligibility criteria**

32
33
34 Randomized trials, cohort studies (retrospective or prospective) and cross-sectional studies on the
35
36 prevalence of PE in patients with AECOPD will be included if the prevalence of PE according to
37
38 the AECOPD purulence status is available. AECOPD purulence status will be categorized as
39
40 definitive purulent AECOPD (purulent AECOPD or purulent sputum), possible purulent
41
42 AECOPD (clinical and/or radiological evidence of tracheobronchial infection or pneumonia), non-
43
44 purulent AECOPD or unknown purulence status AECOPD.
45
46
47
48

49 **Information sources and search strategy**

50
51 MEDLINE, EMBASE and CENTRAL will be searched from inception to March 2023.
52
53
54 Conference abstracts from the American Thoracic Society, American College of Chest Physicians,
55
56
57
58
59

1
2
3 European Respiratory Society, British Thoracic Society, American Society of Hematology,
4
5 International Society on Thrombosis and Haemostasis will be hand searched from January 2000
6
7 to March 2023. There will be no restriction on language. The search strategy will be reviewed by
8
9 a research librarian with expertise in knowledge synthesis and translation, and will be included in
10
11 the supplemental file.
12
13

14 **Study records**

15
16 Two reviewers (V.M. and L.G.) will independently screen all the titles and abstracts for potentially
17
18 eligible studies. Full texts of potentially eligible studies will be obtained and screened by two
19
20 reviewers independently. Both levels of screening will be conducted using Covidence systematic
21
22 review software, Veritas Health Innovation, Melbourne, Australia. Any disagreements will be
23
24 resolved by further discussion or by consulting a third reviewer (G.L.G.). If the same cohort was
25
26 published in multiple papers, the paper with the largest cohort providing the required information
27
28 needed will be selected.
29
30
31

32 **Data items**

33
34 Two independent reviewers (V.M. and L.G.) will extract the data from included papers by using a
35
36 standardized collection form. Collected data will include study characteristics (study ID, reference,
37
38 study design), patients' characteristics [number of patients, age, sex, BMI, mean forced expiratory
39
40 volume in 1 second (FEV1), Global Initiative for Chronic Obstructive Lung Disease (GOLD)
41
42 stage, prior personal or familial venous thromboembolic event, current tobacco use, active cancer
43
44 (defined as current diagnosis of cancer, receiving treatment for cancer or not receiving treatment
45
46 for cancer and not in complete response as per the International Society on Thrombosis and
47
48 Haemostasis Common Data Elements), number of previous AECOPD in the last year, pre-test
49
50 clinical probability, mean D-dimers level, VTE (PE and/or DVT), AECOPD purulence status],
51
52
53
54
55
56
57
58
59
60

1
2
3 proportion of patients who had imaging to rule out VTE, whether or not all patients systematically
4 had diagnostic imaging searching for PE (or VTE) was undertaken, localization of PE, clinical
5 setting (inpatients vs outpatients) and use of independent adjudication. Study authors will be
6 contacted if important information is missing.
7
8
9
10

11 **Outcome measures**

12
13 The primary outcome will be PE at the initial assessment. PE will include symptomatic PE
14 involving segmental branches or more proximal arteries on CTPA, high probability on a planar
15 ventilation/perfusion (V/Q) scan, at least one segmental mismatch or two subsegmental
16 mismatches on a V/Q SPECT (EANM criteria)⁸ and incidental PE found fortuitously on imaging
17 and fatal PE. If the localization of the PE was not mentioned in the article, the study will still be
18 included, and subgroup analyses will be performed. Secondary outcomes will include VTE
19 (proximal DVT and/or PE), proximal DVT and distal DVT, respectively, at the initial assessment.
20 DVT will include DVT of the lower extremity, either symptomatic or incidental. In case it was not
21 mentioned if the DVT was proximal or distal, the study will still be included, and subgroup
22 analyses will be performed. The initial assessment will be defined as the first 48 hours from
23 hospital admission if the patient is admitted, as the first 48 hours from the initial medical evaluation
24 if the patient is managed as an outpatient or as defined by individual studies.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Assessment of risk of bias in included studies**

43
44 The risk of bias of included studies will be evaluated by two independent reviewers (V.M. and
45 L.G.) by using the ROBINS-E tool⁹. Publication bias will be assessed by conducting and
46 evaluating the funnel plot for the primary outcome. A symmetrical funnel plot indicates absence
47 of publication bias.
48
49
50
51
52

53 **Data synthesis**

1
2
3 The prevalence of PE, VTE and DVT, respectively, at initial assessment will be calculated with
4 its 95% confidence interval (CI) by using the binomial exact method¹⁰. Data will be pooled using
5 Review Manager version 5.3 (The Cochrane Collaboration, Oxford, England). Relative risks (RR)
6 with their 95%CI will be calculated by using a Mantel-Haenszel random-effects model to compare
7 the association between the risk of PE in patients with purulent AECOPD and the risk of PE in
8 patients with non-purulent/unknown purulence status AECOPD. Events will be categorized in the
9 definitive purulent AECOPD group if it was mentioned purulent AECOPD or the sputum was
10 described as purulent. Events will be categorized in the possible purulent AECOPD group if there
11 was clinical and/or radiological evidence of tracheobronchial infection or pneumonia. Similar
12 analyses will be conducted to evaluate the association between the risk of VTE and the risk of
13 DVT, respectively, and the AECOPD purulence status. Forest plots will be presented. I^2 will be
14 calculated to evaluate heterogeneity and will be considered significant if I^2 is $> 50\%$. Subgroup
15 analyses will be performed based on the type of study (randomized trials vs prospective cohort
16 studies vs retrospective cohort studies vs cross-sectional studies), systematic search of PE (or
17 VTE) vs no systematic search of PE (or VTE) and localization of PE (or DVT). Sensitivity analyses
18 will be performed by including only studies at low risk of bias. The manuscript will be drafted
19 based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
20 statement.

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 **Patient and public involvement**

45 An experienced patient partner from the Canadian Venous Thromboembolism Research Network
46 (CanVECTOR) patient partner platform revised the protocol and approved the design and conduct
47 of the study, as well as the outcome measures.
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This systematic review with meta-analysis aims at comparing the association between the risk of PE in patients with purulent AECOPD and the risk of PE in patients with non-purulent/unknown purulence status AECOPD. Finding predictors or explanatory factors for PE in patients with AECOPD, such as AECOPD purulence status, could help reduce the need for imaging. If the risk of PE is shown to be lower in patients with purulent AECOPD compared to non-purulent or unknown status AECOPD, this new information may help improve PE diagnostic algorithm in reducing the need for imaging in ruling out PE and thus, improve the care of patients with AECOPD. Moreover, if the prevalence of PE is shown to be very low in patients with purulent AECOPD and being low enough to exclude PE without further investigations, this will certainly reduce the need for imaging in ruling out PE and subsequently, reduce the side effects of CTPA.

Limitations and challenges

We acknowledge that this study may have some limitations and that we may face some challenges when conducting it. First, only a certain number of studies on the prevalence of PE in patients with AECOPD have reported the prevalence of PE based on the AECOPD purulence status. The data included in this systematic review may thus represent a limited proportion of all the data available on the prevalence of PE in patients with AECOPD. Second, the definition of the AECOPD purulence status may not be homogenous across studies which could make it more challenging to pool the data. Finally, although we will analyze all patients with AECOPD, there might be some heterogeneity within this population (e.g. patients admitted vs treated as an outpatient).

CONCLUSION

1
2
3 Improving PE diagnostic algorithm for patients with AECOPD is of high importance to reduce the
4 burden of imaging since PE and AECOPD share similar symptoms, but also to minimize the
5 proportion of missed PE. This systematic review with meta-analysis aims at evaluating if
6 AECOPD purulence status could be a predictor of PE in order to improve the care of patients with
7 COPD.
8
9
10
11
12
13
14
15
16

17 **ETHICS AND DISSEMINATION**

18
19 Since this is a systematic review with meta-analysis of published studies, ethics approval and
20 patients' consent will not be required. Moreover, we aim to submit this work for presentation at
21 an international conference and for publication in a peer-reviewed journal.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BIBLIOGRAPHY

1. Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. *Eur Heart J* 2019;40(42):3453-55. doi: 10.1093/eurheartj/ehz726 [published Online First: 2019/11/08]
2. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;173(1):71-8. doi: 10.1164/rccm.200505-704OC [published Online First: 2005/09/24]
3. Sato R, Hasegawa D, Nishida K, et al. Prevalence of pulmonary embolism in patients with acute exacerbations of COPD: A systematic review and meta-analysis. *The American Journal of Emergency Medicine* 2021;50:606-17. doi: <https://doi.org/10.1016/j.ajem.2021.09.041>
4. Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. *JAMA* 2021;325(1):59-68. doi: 10.1001/jama.2020.23567 [published Online First: 2021/01/06]
5. Jiménez D, Agustí A, Taberner E, et al. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. *JAMA* 2021;326(13):1277-85. doi: 10.1001/jama.2021.14846 [published Online First: 2021/10/06]
6. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine* 2010;363(12):1128-38. doi: 10.1056/NEJMoa0909883

- 1
2
3 7. Connors AF, Jr., Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of
4
5 severe chronic obstructive lung disease. The SUPPORT investigators (Study to
6
7 Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J*
8
9 *Respir Crit Care Med* 1996;154(4 Pt 1):959-67. doi: 10.1164/ajrccm.154.4.8887592
10
11 [published Online First: 1996/10/01]
12
13
14 8. Bajc M, Schümichen C, Grüning T, et al. EANM guideline for ventilation/perfusion single-
15
16 photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism
17
18 and beyond. *European Journal of Nuclear Medicine and Molecular Imaging*
19
20 2019;46(12):2429-51. doi: 10.1007/s00259-019-04450-0
21
22
23 9. ROBINS-E Development Group (Higgins J MR, Rooney A, Taylor K, Thayer K, Silva R,
24
25 Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn
26
27 B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness
28
29 L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J,
30
31 Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T,
32
33 Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk
34
35 Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). 2022 [published Online
36
37 First: Launch version, June 1, 2022]
38
39
40 10. Kohn MA SJ. Sample Size Calculators (website). UCSF CTSI. 2021
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENT

We want to thank Danielle Morneault for her contribution to this protocol.

AUTHORS' CONTRIBUTIONS

VM, FC and GLG conceived the idea and design of this systematic review. VM, LG, KdW, LC, SA, FC, DF and GLG developed the methodology for the protocol of this systematic review. The content of this manuscript was drafted by VM and GLG with input from all members of the authorship team. The manuscript was reviewed by LG, KdW, LC, SA, FC, DF and GLG for important intellectual content. All authors read and approved the final version of the manuscript.

FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

VM is supported by a Professional Postgraduate Training in Research (Fellowship) Award from the Fonds de recherche Santé Québec, a Canadian Institutes of Health Research Fellowship Award and a CanVECTOR fellowship award; CanVECTOR receives grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654). LC is a member of the Canadian Venous Thromboembolism Research Network (CanVECTOR); the Network received grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654). LC holds a Tier 2 research Chair in Thrombosis and Anticoagulation Safety from the University of Ottawa. GLG holds the Chair on Diagnosis of Venous Thromboembolism at the Department of Medicine, University of Ottawa, and a Clinician-Scientist Award from the Heart and Stroke Foundation of Canada.

COMPETING INTERESTS STATEMENT

VM, LG, KdW, SA, FC and DF do not have conflicts of interest. LC's research institution has received honoraria from Bayer, BMS-Pfizer Alliance, The Academy for Continued Advancement in Healthcare Education, Amag Pharmaceutical, LEO Pharma, Sanofi, Valeo Pharma, and Servier. GLG is a co-investigator for a clinical trial from Pfizer and one from Bristol-Myers Squibb and GLG received honoraria from Pfizer, Sanofi and Aspen Pharma.

BMJ Open

Chronic obstructive pulmonary disease exacerbation purulence status and its association with pulmonary embolism: protocol for a systematic review with meta-analysis

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2024-085328.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 10-Jun-2024 |
| Complete List of Authors: | Mai, Vicky; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute Girardi, Laura; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute; University of Insubria, Department of Medicine and Surgery de Wit, Kerstin; Queens University, Department of Emergency Medicine and Medicine Castellucci, Lana; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute Aaron, Shawn; University of Ottawa, Department of Medicine Couturaud, Francis; Centre Hospitalier Universitaire de Brest, Département de Médecine Interne et Pneumologie Fergusson, Dean; Ottawa Hospital Research Institute, Clinical Epidemiology Le Gal, Grégoire; University of Ottawa, Department of Medicine, Ottawa Hospital Research Institute |
| Primary Subject Heading: | Respiratory medicine |
| Secondary Subject Heading: | Cardiovascular medicine, Epidemiology, Haematology (incl blood transfusion) |
| Keywords: | Pulmonary Disease, Chronic Obstructive, Thromboembolism < CARDIOLOGY, Respiratory infections < THORACIC MEDICINE, Epidemiology < THORACIC MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Chronic obstructive pulmonary disease exacerbation purulence status and its association**
4
5 **with pulmonary embolism: protocol for a systematic review with meta-analysis**
6
7

8
9
10 Vicky Mai¹, Laura Girardi^{1,2}, Kerstin de Wit³, Lana A. Castellucci¹, Shawn Aaron⁴, Francis
11
12 Couturaud⁵, Dean Fergusson⁶, Grégoire Le Gal¹
13
14

15
16
17 ¹ Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa,
18
19 Canada.
20

21 ² Department of Medicine and Surgery, University of Insubria, Varese, Italy.
22

23 ³ Department of Emergency Medicine and Medicine, Queens University, Kingston.
24

25
26 ⁴ Department of Medicine, Faculty of Medicine, Division of Respiriology, University of Ottawa,
27
28 Ottawa, Ontario, Canada.
29

30
31 ⁵ INSERM U1304-GETBO, CIC INSERM 1412, Univ_Brest, Département de Médecine Interne
32
33 et Pneumologie, CHU_Brest, Brest, FCRIN INNOVTE, France.
34

35
36 ⁶ Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
37
38
39
40
41
42
43
44

45 **Correspondence to:**

46 Grégoire Le Gal
47 Ottawa Hospital Research Institute – University of Ottawa
48 501 Smyth Road, Ottawa, ON, Canada, K1H 8L6
49 E-mail: glegal@toh.ca
50

51
52 Abstract word count: 290

53 Manuscript word count: 1869
54
55
56
57
58
59
60

ABSTRACT

Introduction: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) increases the risk of pulmonary embolism (PE). AECOPD and PE have similar symptoms which results in a high proportion of patients with AECOPD undergoing imaging to rule out PE. Finding predictors and explanatory factors of PE in AECOPD, such as purulence status, could help reduce the need for imaging. This systematic review with meta-analysis aims to evaluate if there is an association between purulence status in AECOPD and PE diagnosis.

Methods and analysis: MEDLINE, EMBASE and CENTRAL will be searched from database inception to April 2024. Randomized trials, cohort studies and cross-sectional studies on the prevalence of PE in patients with AECOPD will be included if the prevalence of PE based on the AECOPD purulence status is available. There will be no restriction on language. The primary outcome will be PE at the initial assessment and secondary outcomes will be all venous thromboembolism (deep venous thrombosis (DVT) and PE) and DVT, respectively, diagnosed at initial assessment. Relative risks (RR) with their 95% confidence interval (CI) will be calculated by using a Mantel-Haenszel random-effect model to compare the association between the risk of PE and the AECOPD purulence status (purulent vs non-purulent/unknown). Subgroup analyses will be performed based on the type of study, systematic search of PE vs no systematic search of PE and localization of PE. Risk of bias will be evaluated by the ROBINS-E tool, publication bias will be evaluated with the funnel plot. The manuscript will be drafted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.

Ethics and dissemination: This study does not require ethics approval. This work will be submitted for presentation in an international conference and for publication in a peer-reviewed journal.

1
2
3 **Study registration:** PROSPERO, CRD42023459429.
4
5
6
7

8 **Strengths and limitations of this study**
9

- 10
- 11 • An experienced patient partner from the Canadian Venous Thromboembolism Research
12 Network (CanVECTOR) patient partner platform was involved in the protocol elaboration.
13
 - 14 • The acute exacerbation of chronic obstructive pulmonary disease (AECOPD) purulence
15 status may not be homogenous across studies, which may make it more challenging to pool
16 some data.
17
 - 18 • Not all studies report on the prevalence of pulmonary embolism (PE) according to the
19 AECOPD purulence status; consequently, the data included in this systematic review may
20 represent a limited proportion of all the data available on the prevalence of PE in patients
21 with AECOPD.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) increases the risk of pulmonary embolism (PE)¹ due to increased systemic inflammation as well as in the airways². Moreover, PE is associated with a 5-fold increased risk of mortality in patients with chronic obstructive pulmonary disease (COPD)³. Diagnosing PE in the context of AECOPD is challenging for several reasons. First, due to confounding symptoms of AECOPD and PE, it is unknown when PE should be suspected in patients with COPD. Second, even when PE is not suspected, or when another diagnosis is more likely, the prevalence of PE [i.e., 4.5% (PEP⁴ and SLICE⁵)] is not low enough to safely exclude PE on clinical grounds only. Clinical decision rules and D-dimers, when applied to patients with AECOPD and whether PE is suspected or not, have lower clinical utility in AECOPD, since > 65% of the patients would need imaging to rule out PE if standard diagnostic strategy were used⁴. In addition, negative effects are seen with computed tomography pulmonary angiogram (CTPA) such as cost, radiation exposure, contrast-induced nephropathy, and incidental findings. Furthermore, as the severity of the COPD progresses, AECOPD occurs more frequently⁶ and it is expected that the need to rule out PE will become more frequent. Finding predictors and explanatory factors of PE in AECOPD, such as the purulence status, could help reduce the need for imaging. Clinically, it would make sense that if the AECOPD is explained by an infectious process, then the PE would be less likely and conversely, if the AECOPD is unexplained, it would make sense that PE would be more likely to be the explanation for the AECOPD. As a matter of fact, some studies showed a lower risk of PE or VTE in patients with purulent AECOPD⁷⁻⁹.

Thus, the main aim of this systematic review with meta-analysis is to evaluate whether purulence status in AECOPD is associated with PE. We hypothesize that the risk of PE will be lower in purulent AECOPD compared to non-purulent or unknown purulent status AECOPD, since the

1
2
3 etiology of the exacerbation is unknown in up to 30% of the AECOPD¹⁰ and PE could thus be an
4 explanation in those cases. As a secondary aim, we would like to evaluate the association between
5 AECOPD purulence status and the risk of venous thromboembolism (VTE) [deep venous
6 thrombosis (DVT) of the lower extremity and PE] and the risk of DVT, respectively. We
7 hypothesize that the risk of VTE and DVT, respectively, will be lower in patients with purulent
8 AECOPD compared to non-purulent or unknown purulent status AECOPD.
9
10
11
12
13
14
15
16
17
18

19 **Study objectives**

20 *Primary objective*

21
22 The primary objective is to evaluate the risk of PE in patients with purulent AECOPD compared
23 to non-purulent or unknown purulent status AECOPD.
24
25
26
27

28 *Secondary objective*

29
30 The secondary objective is to evaluate the risk of VTE (including DVT of the lower extremity and
31 PE) and the risk of DVT, respectively, in patients with purulent AECOPD compared to non-
32 purulent or unknown purulent status AECOPD.
33
34
35
36
37
38
39

40 **METHODS AND ANALYSIS**

41 **Eligibility criteria**

42
43 Randomized trials, cohort studies (retrospective or prospective) and cross-sectional studies on the
44 prevalence of PE in patients with AECOPD will be included if the prevalence of PE according to
45 the AECOPD purulence status is available. AECOPD purulence status will be categorized as
46 definitive purulent AECOPD (purulent AECOPD or purulent sputum), possible purulent
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AECOPD (clinical and/or radiological evidence of tracheobronchial infection or pneumonia), non-
4 purulent AECOPD or unknown purulence status AECOPD.
5
6

7 **Information sources and search strategy**

8
9
10 MEDLINE, EMBASE and CENTRAL will be searched from inception to April 2024. Conference
11 abstracts from the American Thoracic Society, American College of Chest Physicians, European
12 Respiratory Society, British Thoracic Society, American Society of Hematology, International
13 Society on Thrombosis and Haemostasis will be hand searched from January 2000 to April 2024.
14
15 There will be no restriction on language. The search strategy (**Appendix 1**) will be reviewed by a
16 research librarian with expertise in knowledge synthesis and translation.
17
18
19
20
21
22
23

24 **Study records**

25
26 Two reviewers (V.M. and L.G.) will independently screen all the titles and abstracts for potentially
27 eligible studies. Full texts of potentially eligible studies will be obtained and screened by two
28 reviewers independently. Both levels of screening will be conducted using Covidence systematic
29 review software, Veritas Health Innovation, Melbourne, Australia. Any disagreements will be
30 resolved by further discussion or by consulting a third reviewer (G.L.G.). If the same cohort was
31 published in multiple papers, the paper with the largest cohort providing the required information
32 needed will be selected.
33
34
35
36
37
38
39
40
41

42 **Data items**

43
44 Two independent reviewers (V.M. and L.G.) will extract the data from included papers by using a
45 standardized collection form. Collected data will include study characteristics (study ID, reference,
46 study design), patients' characteristics [number of patients, age, sex, BMI, mean forced expiratory
47 volume in 1 second (FEV1), Global Initiative for Chronic Obstructive Lung Disease (GOLD)
48 stage, prior personal or familial venous thromboembolic event, current tobacco use, active cancer
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (defined as current diagnosis of cancer, receiving treatment for cancer or not receiving treatment
4 for cancer and not in complete response as per the International Society on Thrombosis and
5 Haemostasis Common Data Elements), number of previous AECOPD in the last year, pre-test
6 clinical probability, mean D-dimers level, VTE (PE and/or DVT), AECOPD purulence status],
7 proportion of patients who had imaging to rule out VTE, whether or not all patients systematically
8 had diagnostic imaging searching for PE (or VTE) was undertaken, localization of PE, clinical
9 setting (inpatients vs outpatients) and use of independent adjudication. Study authors will be
10 contacted if important information is missing.
11
12
13
14
15
16
17
18
19
20

21 **Outcome measures**

22
23
24 The primary outcome will be PE at the initial assessment. PE will include symptomatic PE
25 involving subsegmental branches or more proximal arteries on CTPA, high probability on a planar
26 ventilation/perfusion (V/Q) scan, at least one segmental mismatch or two subsegmental
27 mismatches on a V/Q SPECT (EANM criteria)¹¹ and incidental PE found fortuitously on imaging
28 and fatal PE. If the localization of the PE was not mentioned in the article, the study will still be
29 included, and subgroup analyses will be performed. Secondary outcomes will include VTE
30 (proximal DVT and/or PE), proximal DVT and distal DVT, respectively, at the initial assessment.
31
32
33 DVT will include DVT of the lower extremity, either symptomatic or incidental. In case it was not
34 mentioned if the DVT was proximal or distal, the study will still be included, and subgroup
35 analyses will be performed. The initial assessment will be defined as the first 48 hours from
36 hospital admission if the patient is admitted, as the first 48 hours from the initial medical evaluation
37 if the patient is managed as an outpatient or as defined by individual studies.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Assessment of risk of bias in included studies**

1
2
3 The risk of bias of included studies will be evaluated by two independent reviewers (V.M. and
4 L.G.) by using the ROBINS-E tool¹². Publication bias will be assessed by conducting and
5
6 evaluating the funnel plot for the primary outcome. A symmetrical funnel plot indicates absence
7
8 of publication bias.
9
10

11 **Data synthesis**

12
13
14 The prevalence of PE, VTE and DVT, respectively, at initial assessment will be calculated with
15 its 95% confidence interval (CI) by using the binomial exact method¹³ for each study. Data will be
16
17 pooled using Review Manager version 5.3 (The Cochrane Collaboration, Oxford, England).
18
19 Relative risks (RR) with their 95%CI will be calculated by using a Mantel-Haenszel random-
20
21 effects model to compare the association between the risk of PE in patients with purulent AECOPD
22
23 and the risk of PE in patients with non-purulent/unknown purulence status AECOPD. Events will
24
25 be categorized in the definitive purulent AECOPD group if it was mentioned purulent AECOPD
26
27 or the sputum was described as purulent. Events will be categorized in the possible purulent
28
29 AECOPD group if there was clinical and/or radiological evidence of tracheobronchial infection or
30
31 pneumonia. Similar analyses will be conducted to evaluate the association between the risk of VTE
32
33 and the risk of DVT, respectively, and the AECOPD purulence status. Forest plots will be
34
35 presented. If some studies cannot be pooled in the RR analysis evaluating the association between
36
37 the risk of PE and the type of AECOPD, pooled proportions of PE of patients with purulent
38
39 AECOPD and with non-purulent/unknown purulence status AECOPD, respectively, will be
40
41 calculated using StatsDirect statistical software. I^2 will be calculated to evaluate heterogeneity and
42
43 will be considered significant if I^2 is $> 50\%$. Subgroup analyses will be performed based on the
44
45 type of study (randomized trials vs prospective cohort studies vs retrospective cohort studies vs
46
47 cross-sectional studies), systematic search of PE (or VTE) vs no systematic search of PE (or VTE)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and localization of PE (or DVT). Sensitivity analyses will be performed by including only studies
4
5 at low risk of bias. The manuscript will be drafted based on the Preferred Reporting Items for
6
7 Systematic Reviews and Meta-Analysis (PRISMA) statement.
8
9

10 **Patient and public involvement**

11
12 An experienced patient partner from the Canadian Venous Thromboembolism Research Network
13
14 (CanVECTOR) patient partner platform revised the protocol and approved the design and conduct
15
16 of the study, as well as the outcome measures.
17
18
19
20

21 **ETHICS AND DISSEMINATION**

22
23 Since this is a systematic review with meta-analysis of published studies, ethics approval and
24
25 patients' consent will not be required. We aim to submit this work for presentation at an
26
27 international conference and for publication in a peer-reviewed journal.
28
29
30
31

32 **DISCUSSION**

33
34 This systematic review with meta-analysis aims at comparing the association between the risk of
35
36 PE in patients with purulent AECOPD and the risk of PE in patients with non-purulent/unknown
37
38 purulence status AECOPD. Finding predictors or explanatory factors for PE in patients with
39
40 AECOPD, such as AECOPD purulence status, could help reduce the need for imaging. If the risk
41
42 of PE is shown to be lower in patients with purulent AECOPD compared to non-purulent or
43
44 unknown status AECOPD, this new information may help improve PE diagnostic algorithm in
45
46 reducing the need for imaging in ruling out PE and thus, improve the care of patients with
47
48 AECOPD. Moreover, if the prevalence of PE is shown to be very low in patients with purulent
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AECOPD and being low enough to exclude PE without further investigations, this will certainly
4
5 reduce the need for imaging in ruling out PE and subsequently, reduce the side effects of CTPA.
6

7 We acknowledge that this study may have some limitations and that we may face some challenges
8
9 when conducting it. First, only a certain number of studies on the prevalence of PE in patients with
10
11 AECOPD have reported the prevalence of PE based on the AECOPD purulence status. The data
12
13 included in this systematic review may thus represent a limited proportion of all the data available
14
15 on the prevalence of PE in patients with AECOPD. Second, the definition of the AECOPD
16
17 purulence status may not be homogenous across studies which could make it more challenging to
18
19 pool the data. Finally, although we will analyze all patients with AECOPD, there might be some
20
21 heterogeneity within this population (e.g. patients admitted vs treated as an outpatient).
22
23

24
25 Improving PE diagnostic algorithm for patients with AECOPD is of high importance to reduce the
26
27 burden of imaging since PE and AECOPD share similar symptoms, but also to minimize the
28
29 proportion of missed PE. This systematic review with meta-analysis aims at evaluating if
30
31 AECOPD purulence status could be a predictor of PE in order to improve the care of patients with
32
33 COPD.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

We want to thank Danielle Morneau for her contribution to this protocol by revising the protocol and approving the design and conduct of the study.

CONTRIBUTORS

VM, FC and GLG conceived the idea and design of this systematic review. VM, LG, KdW, LC, SA, FC, DF and GLG developed the methodology for the protocol of this systematic review. The content of this manuscript was drafted by VM and GLG with input from all members of the authorship team. The manuscript was reviewed by LG, KdW, LC, SA, FC, DF and GLG for important intellectual content. All authors read and approved the final version of the manuscript.

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

VM is supported by a Professional Postgraduate Training in Research (Fellowship) Award from the Fonds de recherche Santé Québec, a Canadian Institutes of Health Research Fellowship Award and a CanVECTOR fellowship award; CanVECTOR receives grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654). LC is a member of the Canadian Venous Thromboembolism Research Network (CanVECTOR); the Network received grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654). LC holds a Tier 2 research Chair in Thrombosis and Anticoagulation Safety from the University of Ottawa. GLG holds the Chair on Diagnosis of Venous Thromboembolism at the Department of

1
2
3 Medicine, University of Ottawa, and a Clinician-Scientist Award from the Heart and Stroke
4
5 Foundation of Canada.
6
7
8
9

10 **COMPETING INTERESTS**

11
12 VM, LG, KdW, SA, FC and DF do not have conflicts of interest. LC's research institution has
13
14 received honoraria from Bayer, BMS-Pfizer Alliance, The Academy for Continued Advancement
15
16 in Healthcare Education, Amag Pharmaceutical, LEO Pharma, Sanofi, Valeo Pharma, and Servier.
17
18 GLG is a co-investigator for a clinical trial from Pfizer and one from Bristol-Myers Squibb and
19
20 GLG received honoraria from Pfizer, Sanofi and Aspen Pharma.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. *Eur Heart J* 2019;40(42):3453-55. doi: 10.1093/eurheartj/ehz726 [published Online First: 2019/11/08]
2. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;173(1):71-8. doi: 10.1164/rccm.200505-704OC [published Online First: 2005/09/24]
3. Sato R, Hasegawa D, Nishida K, et al. Prevalence of pulmonary embolism in patients with acute exacerbations of COPD: A systematic review and meta-analysis. *The American Journal of Emergency Medicine* 2021;50:606-17. doi: <https://doi.org/10.1016/j.ajem.2021.09.041>
4. Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. *JAMA* 2021;325(1):59-68. doi: 10.1001/jama.2020.23567 [published Online First: 2021/01/06]
5. Jiménez D, Agustí A, Taberner E, et al. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. *JAMA* 2021;326(13):1277-85. doi: 10.1001/jama.2021.14846 [published Online First: 2021/10/06]
6. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine* 2010;363(12):1128-38. doi: 10.1056/NEJMoa0909883

- 1
2
3 7. Choi KJ, Cha SI, Shin KM, et al. Prevalence and predictors of pulmonary embolism in Korean
4 patients with exacerbation of chronic obstructive pulmonary disease. *Respiration*
5 2013;85(3):203-09.
6
7
8
9
10 8. Dentali F, Pomero F, Micco PD, et al. Prevalence and risk factors for pulmonary embolism in
11 patients with suspected acute exacerbation of COPD: a multi-center study. *European*
12 *journal of internal medicine* 2020;80:54-59. doi: 10.1016/j.ejim.2020.05.006 [published
13 Online First: 2020/06/01]
14
15
16
17
18
19 9. Liu X, Jiao X, Gong X, et al. Prevalence, Risk Factor and Clinical Characteristics of Venous
20 Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective
21 Multicenter Study. *Int J Chron Obstruct Pulmon Dis* 2023;18:907-17. doi:
22 10.2147/copd.S410954 [published Online First: 2023/05/24]
23
24
25
26
27
28 10. Connors AF, Jr., Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of
29 severe chronic obstructive lung disease. The SUPPORT investigators (Study to
30 Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J*
31 *Respir Crit Care Med* 1996;154(4 Pt 1):959-67. doi: 10.1164/ajrccm.154.4.8887592
32 [published Online First: 1996/10/01]
33
34
35
36
37
38
39
40 11. Bajc M, Schümichen C, Grüning T, et al. EANM guideline for ventilation/perfusion single-
41 photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism
42 and beyond. *European Journal of Nuclear Medicine and Molecular Imaging*
43 2019;46(12):2429-51. doi: 10.1007/s00259-019-04450-0
44
45
46
47
48
49 12. ROBINS-E Development Group (Higgins J MR, Rooney A, Taylor K, Thayer K, Silva R,
50 Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn
51 B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness
52
53
54
55
56
57
58
59
60

1
2
3 L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J,
4
5 Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T,
6
7 Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk
8
9 Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). 2022 [published Online
10
11 First: Launch version, June 1, 2022]
12
13

14
15 13. Kohn MA SJ. Sample Size Calculators (website). UCSF CTSI. 2021
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Chronic obstructive pulmonary disease exacerbation purulence status and its association**
4
5 **with pulmonary embolism: protocol for a systematic review with meta-analysis**
6

7 **Supplemental file**
8
9

10
11
12 Vicky Mai¹, Laura Girardi^{1,2}, Kerstin de Wit³, Lana A. Castellucci¹, Shawn Aaron⁴, Francis
13
14 Couturaud⁵, Dean Fergusson⁶, Grégoire Le Gal¹
15
16

17
18
19 ¹ Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa,
20
21 Canada.
22

23
24 ² Department of Medicine and Surgery, University of Insubria, Varese, Italy.
25

26
27 ³ Department of Emergency Medicine and Medicine, Queens University, Kingston.
28

29
30 ⁴ Department of Medicine, Faculty of Medicine, Division of Respiriology, University of Ottawa,
31
32 Ottawa, Ontario, Canada.

33
34 ⁵ INSERM U1304-GETBO, CIC INSERM 1412, Univ_Brest, Département de Médecine Interne
35
36 et Pneumologie, CHU_Brest, Brest, FCRIN INNOVTE, France.

37
38 ⁶ Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
39
40
41
42
43
44
45
46

47 **Corresponding author:**

48 Grégoire Le Gal
49 Ottawa Hospital Research Institute – University of Ottawa
50 501 Smyth Road, Ottawa, ON, Canada, K1H 8L6
51 E-mail: glegal@toh.ca
52
53
54
55
56
57
58
59
60

APPENDIX 1**Search strategy MEDLINE**

1. "Chronic obstructive pulmonary disease".ab,kw,ti.
2. Pulmonary disease, Chronic obstructive/
3. "Chronic obstructive lung disease".ab,kw,ti.
4. "Chronic obstructive airway disease".ab,kw,ti.
5. "Chronic airflow obstruction".ab,kw,ti.
6. COPD.ab,kw,ti.
7. "Chronic bronchitis".ab,kw,ti.
8. Bronchitis, Chronic/
9. "Pulmonary emphysema".ab,kw,ti.
10. Pulmonary emphysema/
11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
12. "Venous thrombos*".ab,kw,ti.
13. Venous thrombosis/
14. "Vein thrombosis".ab,kw,ti.
15. "Vein thromboembolism".ab,kw,ti.
16. "Pulmonary embolism".ab,kw,ti.
17. Pulmonary embolism/
18. "Pulmonary embolisms".ab,kw,ti.
19. "Pulmonary thromboembolism".ab,kw,ti.
20. "Lung embolism".ab,kw,ti.
21. "Lung embolisms".ab,kw,ti.

1
2
3 22. "Lung thromboembolism".ab,kw,ti.
4

5 23. "Venous thromboembolism".ab,kw,ti.
6

7 24. Venous thromboembolism/
8

9
10 25. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
11
12 OR #23 OR #24
13

14
15 #11 AND #25
16

17
18
19 **Search strategy Embase**
20

21 1. "Chronic obstructive pulmonary disease".ab,ti,kw
22

23 2. "Chronic obstructive pulmonary disease"/
24

25 3. "Chronic obstructive lung disease".ab,ti,kw
26

27 4. "Chronic obstructive airway disease".ab,ti,kw
28

29 5. "Chronic airflow obstruction".ab,ti,kw
30

31 6. COPD.ab,ti,kw
32

33 7. "Chronic bronchitis".ab,ti,kw
34

35 8. "Chronic bronchitis"/
36

37 9. "Pulmonary emphysema".ab,ti,kw
38

39 10. "Pulmonary emphysema"/
40

41 11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
42

43 12. "Venous Thrombos*".ti,ab,kw
44

45 13. "Venous thromboembolism".ti,ab,kw
46

47 14. "Vein Thrombos*".ti,ab,kw
48

49 15. "Vein thromboembolism".ti,ab,kw
50
51
52
53
54
55
56
57
58
59
60

1
2
3 16. "Vein thrombosis"/

4
5 17. "Pulmonary embolism".ti,ab,kw

6
7 18. "Pulmonary embolisms".ti,ab,kw

8
9 19. "Pulmonary thromboembolism".ti,ab,kw

10
11 20. "Lung embolism".ti,ab,kw

12
13 21. "Lung embolisms".ti,ab,kw

14
15 22. "Lung thromboembolism".ti,ab,kw

16
17 23. "Lung embolism"/

18
19 24. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22

20
21
22
23 OR #23

24
25 #11 AND #24

26
27
28
29
30
31 **Search strategy CENTRAL**

32
33 1. "Chronic obstructive pulmonary disease".ab,kw,ti.

34
35 2. Pulmonary disease, Chronic obstructive/

36
37 3. "Chronic obstructive lung disease".ab,kw,ti.

38
39 4. "Chronic obstructive airway disease".ab,kw,ti.

40
41 5. "Chronic airflow obstruction".ab,kw,ti.

42
43 6. COPD.ab,kw,ti.

44
45 7. "Chronic bronchitis".ab,kw,ti.

46
47 8. Bronchitis, Chronic/

48
49 9. "Pulmonary emphysema".ab,kw,ti.

50
51 10. Pulmonary emphysema/

1
2
3 11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
4

5 12. “Venous thrombos*”.ab,kw,ti.
6

7 13. Venous thrombosis/
8

9 14. “Vein thrombosis”.ab,kw,ti.
10

11 15. “Vein thromboembolism”.ab,kw,ti.
12

13 16. “Pulmonary embolism”.ab,kw,ti.
14

15 17. Pulmonary embolism/
16

17 18. “Pulmonary embolisms”.ab,kw,ti.
18

19 19. “Pulmonary thromboembolism”.ab,kw,ti.
20

21 20. “Lung embolism”.ab,kw,ti.
22

23 21. “Lung embolisms”.ab,kw,ti.
24

25 22. “Lung thromboembolism”.ab,kw,ti.
26

27 23. “Venous thromboembolism”.ab,kw,ti.
28

29 24. Venous thromboembolism/
30

31 25. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
32

33 OR #23 OR #24
34

35 #11 AND #25
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item |
|-----------------------------------|---------|---|
| ADMINISTRATIVE INFORMATION | | |
| Title: | | |
| Identification | 1a | Identify the report as a protocol of a systematic review p.1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such NA |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number p.3 |
| Authors: | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author p.1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review p.11 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments NA |
| Support: | | |
| Sources | 5a | Indicate sources of financial or other support for the review p.11 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor NA |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol NA |
| INTRODUCTION | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known p.4 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) p.5 |
| METHODS | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review p.5-6 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage p.6 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated p.6 and supplemental file |
| Study records: | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review p.6 |

| | | |
|------------------------------------|-----|---|
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) p.6 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators p.6 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications p.6-7 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale p.7 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis p.8 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised p.8 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ) p.8 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) p.8 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned p.8 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) p.8 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) NA |

***It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015 Jan 2;349(jan02 1):g7647.*